Sign Up

InspireMD Announces Combined Financings of $58 Million

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the Company has raised approximately $58 million in combined gross proceeds through an equity private placement ("PIPE") financing and the exercise of warrants that were triggered by the Company's premarket application approval ("PMA") of the CGuard Prime carotid stent system by the U.S. Food and Drug Administration ("FDA").

The PIPE, with aggregate gross proceeds of $40.1 million, was led by current investors OrbiMed and Marshall Wace, with strong participation from new and existing investors, as well as InspireMD board members. Pursuant to the securities purchase agreement, the Company has agreed to issue an aggregate of 16,556,184 shares of common stock and, if applicable, pre-funded warrants, at a purchase price of $2.42 per share (less, when applicable, $0.0001 for each pre-funded warrant issued at closing). The warrant exercise generated gross proceeds of $17.9 million, which was triggered by the receipt of the PMA from the FDA. This is the second tranche of warrants that were originally issued as part of the Company's milestone-based financing announced in May 2023.

"This transaction accomplished several key objectives to fund our growth plan as we launch CGuard Prime into the U.S. market," said Marvin Slosman, CEO of InspireMD. "We fortified our shareholder base, broadened our investor reach and significantly strengthened our balance sheet giving us the ability to rapidly expand our commercial growth. With a strong balance sheet, favorable reimbursement environment including a national coverage decision ("NCD") for carotid stenting and best in class clinical trial data generated from our pivotal U.S. study recently resulting in PMA approval, InspireMD is now poised to become the leader of the carotid intervention market."

In connection with the PIPE, the Company entered into a registration rights agreement pursuant to which the Company will subsequently file a registration statement to register the resale of common stock purchased in the transaction and the common stock underlying the pre-funded warrants. The closing of the PIPE is expected to occur by August 1, 2025, subject to customary closing conditions.

InspireMD currently intends to use the net proceeds from the PIPE transaction to fund its operations, including, but not limited to, sales and ...